Developing new treatment strategies for hormone receptor positive breast cancer using patient-derived models.
Official title: Using patient-derived co-culture models of breast cancer to develop new treatment strategies targeting succinate signaling.
Funded at Beth Israel Deaconess Medical Center · NIH-10947728 · Data updated 2026-11-12
This study is working on better ways to understand hormone receptor positive breast cancer by using tiny lab-grown versions of tumors from patients, which could help create more personalized and effective treatments for people like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $444,569 |
| NIH project number | 1R21CA292302-01 |
| Project ID | NIH-10947728 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hormone receptor positive breast cancer, particularly those with recurrent or relapsed disease.
✕Less likely to help
Patients with non-hormone receptor positive breast cancer or those who are not experiencing recurrence may not benefit from this research.
What this research studies
This research focuses on creating more accurate models of hormone receptor positive (HR+) breast cancer by using patient-derived tumor organoids and cancer-associated fibroblasts. These models aim to better reflect the diversity of patients and the complexities of the tumor microenvironment, which are often overlooked in current studies. By improving the representation of recurrent and relapsed HR+ breast cancers, the research seeks to enhance understanding of treatment responses and develop new therapeutic strategies. Patients may benefit from more effective and personalized treatment options based on these improved models.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients with hormone receptor positive breast cancer.
How similar studies have gone: Previous research has shown success in developing patient-derived models for other cancers, suggesting potential for similar advancements in HR+ breast cancer.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Muranen, Taru Eliisa — Beth Israel Deaconess Medical Center
- Study coordinator: Muranen, Taru Eliisa
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.